![]() |
|
|
Vol. 301, Issue 2, 661-671, May 2002
-Opioid Receptor Ligand
Department of Pharmacology and Toxicology, University of Arkansas
for Medical Sciences, Little Rock, Arkansas
Recent evidence indicates that the well established
-opioid
antagonist TIPP (H-Tyr-Tic-Phe-Phe-OH) also displays agonist activity
in several cellular models. Therefore, it is possible that TIPP, and
structurally related compounds, might represent a novel class of opioid
agonists exhibiting unique characteristics. The purpose of this study
was to examine the properties of TIPP at selected points of the signal
transduction pathway (i.e., receptor binding, G-protein activation, and
effector regulation) in GH3DORT cells (GH3
cells expressing
-opioid receptors) and compare them with
that of an established
-opioid agonist,
[D-Pen2,D-Pen5]-enkephalin
(DPDPE). DPDPE exhibited properties of an agonist in all assays. In
contrast, TIPP demonstrated characteristics of an agonist, antagonist,
or inverse agonist, depending on the step in the signal transduction
cascade examined and the assay conditions employed. In receptor binding
assays, the addition of guanine nucleotides and sodium ions increased
the affinity of TIPP for
-opioid receptors in both membrane
preparations and digitonin-permeabilized cells, which is characteristic
of an inverse agonist. In assays measuring G-protein activation, TIPP
failed to stimulate guanosine
5'-O-(3-[35S]thio)triphosphate
([35S]GTP
S) binding in membrane preparations, which is
consistent with an antagonist profile. However, when using cells
semi-permeabilized with digitonin, TIPP exhibited properties of
an agonist, producing concentration-dependent, antagonist-reversible
stimulation of [35S]GTP
S binding. Finally, in assays
examining regulation of the intracellular effector adenylyl cyclase,
TIPP exhibited characteristics of an agonist, producing inhibition of
enzyme activity in both membrane preparations and whole cells.
Therefore, although DPDPE and TIPP act similarly as agonists to
regulate the intracellular effector adenylyl cyclase, they demonstrate
significant differences in the signal transduction cascade preceding
this final point of convergence.
This article has been cited by other articles:
![]() |
P. Tryoen-Toth, F. M. Decaillot, D. Filliol, K. Befort, L. H. Lazarus, P. W. Schiller, H. Schmidhammer, and B. L. Kieffer Inverse Agonism and Neutral Antagonism at Wild-Type and Constitutively Active Mutant Delta Opioid Receptors J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 410 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Townsend IV, P. S. Portoghese, and D. R. Brown Characterization of Specific Opioid Binding Sites in Neural Membranes from the Myenteric Plexus of Porcine Small Intestine J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 385 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-G. Liu and P. L. Prather Chronic Agonist Treatment Converts Antagonists into Inverse Agonists at delta -Opioid Receptors J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1070 - 1079. [Abstract] [Full Text] [PDF] |
||||